Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 million in an oversubscribed Series B financing led by B Capital Group and Sanabil Investments. The funding round includes returning investors DCVC, BV, Tencent, Y Combinator, Dolby Ventures, AME Cloud Ventures, as well as new backing from two top ten global insurance companies. This brings the total amount of capital raised to date to almost $175 million. The company has appointed Raj Ganguly of B Capital Group as a new board member and Hani Enaya of Sanabil as a board observer.